Zoetis has a U.S. pet problem
- Zoetis is a global animal health leader with about 300 product lines sold in over 100 countries.
- The core issue is the U.S. companion animal business, where Q1 2026 sales fell 11%.
- International revenue grew 17% in Q1 2026, helped by currency and calendar-related changes.
- Management cut full-year organic operational revenue growth guidance to 2% to 5%.
- The top five product lines were about 42% of 2025 revenue, so a few franchises matter a lot.
Strong franchise, weaker pet demand
Zoetis still has a strong base. It sells trusted animal medicines, vaccines, and diagnostics across pets and livestock. It also has scale, a large sales force, and more than 5,500 patents. That gives the company real staying power.
The problem is that the most important engine is slowing. In Q1 2026, U.S. revenue fell 8%, and U.S. companion animal revenue fell 11%. Management blamed lower vet clinic traffic, more price-sensitive pet owners, stronger competition, and weaker buying from distributors and retailers.
The bull case now needs the U.S. weakness to be mostly a first-half 2026 problem. It also needs Librela and Simparica to stabilize and then grow again. International revenue grew 17% in Q1 2026, or 9% excluding currency effects, and livestock was stronger, so Zoetis is not a one-market company.
The bear case is that the old playbook may be breaking. Management said new competitors are not expanding the overall market like they did in the past. Full-year organic operational revenue growth guidance is now 2% to 5%, and that includes a 200 to 250 basis point calendar benefit. The next key proof point is whether Q2 shows the U.S. decline has bottomed.
Vet trust drives the sales
Zoetis makes money by discovering, making, and selling animal health products. Most products are medicines, vaccines, diagnostics, and related services. Customers include veterinarians, livestock producers, distributors, retail channels, and e-commerce channels.
The company works through veterinarians because many products are prescription products. That matters because vets often influence what pet owners and farmers buy. Zoetis also has technical specialists who help customers use the products correctly.
The model works best when Zoetis launches products that treat unmet needs, then uses its sales force and brand trust to build loyalty. Apoquel, Simparica, Cytopoint, Librela, and Solensia show that pattern. The risk is that premium products are harder to sell when pet owners push back on price.
Concentration is another pressure point. The top two product lines, Simparica and Apoquel, were about 28% of 2025 revenue. The top five product lines were about 42%. If competition, safety questions, or generic pressure hit those lines, the whole company feels it.
The franchises that matter
Simparica franchise
This parasiticide line protects pets from fleas, ticks, and related parasites. It is one of Zoetis's top two product lines, but Q1 2026 commentary points to more competition and pressure in the U.S.
Apoquel
Apoquel is a major dermatology product for itchy skin and allergic disease in dogs. It is a top product line, but key dermatology revenue fell in Q1 2026.
Cytopoint
Cytopoint is another major dermatology product. It adds breadth to Zoetis's pet allergy franchise, but the whole dermatology category is now facing weaker demand and competition.
Librela and Solensia
These osteoarthritis pain antibody products opened a newer pain market for dogs and cats. The franchise has been weak, and management says the recovery depends on education and stabilization.
Vaccines
Vaccines serve both companion animals and livestock. In Q1 2026, International companion animal vaccine demand and livestock vaccine demand helped offset U.S. pet weakness.
Ceftiofur line and livestock medicines
Zoetis sells anti-infectives and other medicines for cattle, swine, poultry, fish, and other species. Livestock revenue grew in Q1 2026 and gives the company useful diversification.
Two big markets, one weak spot
Mix is based on Q1 2026 revenue from Zoetis's latest Form 10-Q. U.S. revenue was $1.09 billion, International revenue was $1.149 billion, and contract manufacturing and human health was $23 million.
What could break the thesis
U.S. pet demand stays weak
High impact · High oddsThe U.S. is the key pressure point right now. In Q1 2026, U.S. revenue fell 8%, and U.S. companion animal revenue fell 11%. If pet owners keep skipping visits or trading down from premium products, Zoetis may struggle to return to its old growth rate.
Competition stops growing the market
High impact · High oddsZoetis used to benefit when innovation expanded animal health categories. Management now says new entrants are not expanding the overall market in the same way. That raises the risk of share loss, discounting, and lower growth in dermatology, parasiticides, and pain products.
Librela recovery fails
Medium impact · Medium oddsLibrela and Solensia were meant to be major growth products in pet osteoarthritis pain. The franchise has declined, and earlier management comments tied part of the weakness to safety and benefit-risk concerns spreading online. If education does not rebuild confidence, the pain opportunity could stay smaller than expected.
Top product concentration bites
High impact · Medium oddsThe top two product lines were about 28% of 2025 revenue, and the top five were about 42%. That makes Zoetis less diversified than the long product list suggests. A problem in a few big lines can move total company results.
Distributor and channel swings distort demand
Medium impact · Medium oddsQ1 2026 was hurt by distributor and retail purchasing patterns, reflecting lower end-market demand. It is still unclear how much of the U.S. decline came from true pet owner demand versus channel inventory changes. If destocking is not over, reported sales could stay choppy.
Regulation, supply, and currency pressure
Medium impact · Medium oddsZoetis sells regulated products in many countries and runs a global supply chain. The company also flagged tariffs, disease outbreaks, cybersecurity, foreign exchange, and possible PFAS chemical rules as risks. These may not drive the main thesis today, but they can hurt margins or delay products.
In one breath
What does Zoetis do?
Zoetis makes and sells animal health products. Its main areas include medicines, vaccines, diagnostics, and related services for pets and livestock.
Why is Zoetis under pressure in 2026?
The biggest issue is the U.S. companion animal business. In Q1 2026, management pointed to lower vet traffic, more price-sensitive pet owners, tougher competition, and distributor or retail buying patterns.
Is Zoetis only a pet company?
No. Companion animal products are the larger part of the business, but Zoetis also sells livestock products for cattle, swine, poultry, fish, sheep, and other animals. In Q1 2026, livestock was stronger than the U.S. pet business.
What should investors watch next?
Watch whether Q2 shows the U.S. decline is bottoming. Also watch Librela, Simparica, full-year guidance, and whether Zoetis needs more promotions to defend share.